Comparing Effect of Short Sleep Duration on Weight Loss of Overweight and Obese Women Attending a Weight Loss Program

Comparing the Effect of Short Sleep Duration on Weight Loss of Overweight and Obese Women Attending a Weight Loss Program: A 12 Week Randomized Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03120260

Enrollment

Registered

2017-04-19

Start date

2017-06-15

Completion date

2017-11-27

Last updated

2018-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Overweight

Keywords

Caloric Restriction, weight loss, sleep

Brief summary

The purpose of the present study is to evaluate the effect of sleep duration on weight loss of obese and overweight adult when they are in a weight loss plan (NovinDiet Protocol). The investigators aim is to compare the effects of short term sleep duration with normal sleep duration with respect to body weight (and abdominal adiposity).

Interventions

OTHERDiet

Intervention 'Diet+ short sleep versus normal sleep

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Must be female * Must have \< 7 hour sleep per night * Must be 18-45 years of age. * Must have Body mass index (BMI) between 27-35 kg/ m². * Must be able to have moderate exercise. * Must be interested to have weight loss.

Exclusion criteria

* Participating in a research project involving weight loss or physical activity in the previous six months. * Pregnancy or lactation during the previous 6 months, or planned pregnancy in the next six months. * Taking medication that could affect metabolism or change body weight. * Report heart problems, chest pain, and cancer within the last five years. * Smoking * Menopause * Diagnosis of any chronic disease such as fatty liver, cancer, chemo/radio therapy, heart disease, immune compromised conditions, abnormal thyroid hormone level.

Design outcomes

Primary

Measure	Time frame	Description
weight loss	12 Weeks	kg

Secondary

Measure	Time frame	Description
Body mass index reduction	12 Weeks	kg/m2
Fasting plasma glucose level	12 Weeks	mmol/l
lipid profiles	12 Weeks	mmol/l
Insulin resistance (HOMA)	12 Weeks	score
liver enzymes (SGOT, SGPT)	12 Weeks	U/l

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026